PARP9 and breast cancer: Importantly, high expression levels of both BAL1 and BAL2 were strongly associated with favorable prognosis across all patient groups as well as specific subtypes including ER-positive, ER-negative, Basal-like, luminal B-like, HER2- and HER2 + BC.